lapatinib has been researched along with zibotentan in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (zibotentan) | Trials (zibotentan) | Recent Studies (post-2010) (zibotentan) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 67 | 18 | 46 |
| Protein | Taxonomy | lapatinib (IC50) | zibotentan (IC50) |
|---|---|---|---|
| Endothelin-1 receptor | Homo sapiens (human) | 0.021 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jensen, RT; Mantey, SA; Moody, TW; Moreno, P; Ramos-Alvarez, I; Ridnour, L; Wink, D | 1 |
2 other study(ies) available for lapatinib and zibotentan
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Receptor, Endothelin B; Receptor, ErbB-2; Transcriptional Activation | 2017 |